Trajectory Analysis of Neutrophil to Lymphocyte Ratio（NLR） and Its Association With Efficacy of Immunochemotherapy in Esophageal Squamous Cell Carcinoma: A Retrospective Cohort Study
Sponsor study identifier
observational
100
1 country
1
Study Start
November 1, 2022
Actual (reported)Primary Completion
June 30, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
July 31, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Conduct a retrospective and prospective study to confirm the association between blood cells counts and the efficacy and safety in immunochemotherapy in patients with advanced esophageal cancer.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
July 31, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
November 1, 2022
Actual (reported)November 5, 2023
Actual (reported)November 9, 2023
Actual (reported)June 30, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
July 31, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Overall survival and disease-free survival.
Overall survival rate
From the date of diagnosis to the date of death, assessed up to 100 months
Pathologic complete response rate
Three to five working days after surgery
Objective Response Rate (ORR)
Up to 24 weeks
All patients who underwent neoadjuvant immunochemotherapy at Guangdong provincial peoples hospital and The First Affiliated Hospital of Shantou University.
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, 510080, China
Blood cell counts recorded at baseline and after the first cycle of treatment
guibin Qiao, MD
Guangdong Provincial People's Hospital
First Submitted
November 5, 2023
First Posted
November 9, 2023
Study Start
November 1, 2022
Actual (reported)Primary Completion
June 30, 2024
Estimated (date passed)Pathological Tumor and Lymph Node Responses After Neoadjuvant Immunochemotherapy in Initially-unresectable NSCLC
Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous Cell
Major pathological response
Three to five working days after surgery
Event-free survival
From the date of treatment initiation to the date of first progression (local recurrence of tumor or distant metastasis) or death from any cause, assessed up to 100 months
Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
July 31, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
December 28, 2023
Record last verified: 2023-12
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: